Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

The document concludes that gender-affirming treatments are essential for transgender individuals and outlines safe hormone therapy practices.

The document concludes that various findings in rheumatology offer insights into disease severity, treatment responses, and potential risks in medication, with some limitations due to unspecified participant numbers.

Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.

Male hormones may play a role in the development of heart disease, and more research is needed to understand their effects.

Young Indian women with PCOS have a higher risk of heart disease, not linked to thyroid function but to higher levels of certain fats and homocysteine.

Women with irregular periods have a higher risk of heart disease.

Tacrolimus causes fewer acute rejections than cyclosporin A in kidney transplants but doesn't necessarily improve kidney function after one year; cardiovascular risks and side effects vary between the two drugs.

Testosterone therapy in transgender men has both desired effects like increased muscle mass and potential health risks such as higher cardiovascular risk.

PCOS in lean women is a serious health condition with implications beyond fertility, affecting metabolism and increasing cardiovascular disease risk.

Some skin conditions may increase the risk of heart disease, and understanding their connection could lead to better treatments.

JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.

Dutasteride for hair loss might increase the risk of a rare stroke type.

The guideline recommends mental health involvement in diagnosing gender identity disorder and outlines hormone and surgical treatment protocols, emphasizing safety, informed consent, and long-term monitoring.

Hormone therapy is essential for transgender individuals but requires careful management due to possible metabolic effects.

The document suggests that clinical trials for PCOS should focus on meaningful primary outcomes like live birth rates, rather than less reliable surrogate markers.

Testosterone therapy seems safe and effective for transgender men with proper care, but more long-term research is needed.

Hormonal treatments can improve acne, but they come with potential side effects and risks.

Testosterone therapy seems safe for short-term use in postmenopausal women with low sexual desire, but more research on long-term effects is needed.

Polycystic Ovary Syndrome (PCOS) can lead to diabetes, heart disease, cancer, and mental health problems.

Managing metabolic syndrome needs both lifestyle changes and medical treatments.

The European Society of Endocrinology advises individualized long-term management for PCOS, focusing on lifestyle changes, accurate diagnosis, and treatments for associated health risks and symptoms.

The guidelines suggest lifestyle changes, diet adjustments, and personalized medication to manage dyslipidemia and reduce heart disease risk.

The NAMS 2014 recommendations guide healthcare providers on treating health issues in midlife women, emphasizing individualized care and informed decision-making.

Hormone therapy for trans individuals is effective and generally safe in the short term.

Testosterone therapy seems safe for postmenopausal women for a few years, but more research is needed for long-term effects.

Certain genetic markers linked to reproductive potential were identified by their impact on a protein's ability to bind to genes.

The oral contraceptive ethinylestradiol/chlormadinone acetate is effective in reducing acne and improving other skin conditions related to high androgen levels.

Some skin diseases may indicate a higher risk of metabolic syndrome and related health issues.

Aldesleukin can treat certain cancers and increase HIV patient CD4+ counts but often causes severe side effects.